Allakos Newsroom

Analysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)

TipRanksMay 14 05:31 ET

Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions

Yahoo FinanceMay 10 16:02 ET

NOTV, BFRI and CPOP Among Pre-market Losers

Seeking AlphaMay 10 08:30 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Electrocore (ECOR), Disc Medicine (IRON) and Allakos (ALLK)

TipRanksMay 10 08:10 ET

Barclays Sticks to Its Sell Rating for Allakos (ALLK)

TipRanksMay 10 06:05 ET

Allakos Buy Rating: Clinical Promise and Financial Stability Drive Positive Outlook

TipRanksMay 10 00:55 ET

Allakos | 10-Q: Quarterly report

Futu NewsMay 9 17:15 ET · Announcements

Express News | Allakos Q1 2024 GAAP EPS $(0.81) Misses $(0.44) Estimate

BenzingaMay 9 16:54 ET

Express News | Allakos - Continues to Expect to End 2024 With Total Cash, Cash Equivalents and Investments in Range of $81 to $86 Mln

ReutersMay 9 16:27 ET

Express News | Allakos Inc - Reiterates Restructuring Activities Will Extend Cash Runway Into Mid-2026

ReutersMay 9 16:27 ET

Express News | Allakos Q1 Operating Income USD -73.069 Million

ReutersMay 9 16:02 ET

Express News | Allakos Q1 Net Income USD -71.146 Million

ReutersMay 9 16:02 ET

Press Release: Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (Nasdaq: ALLK), a biotechnology com

Dow JonesMay 9 16:02 ET

Allakos 1Q Loss/Shr 81c >ALLK

Allakos 1Q Loss/Shr 81c >ALLK

Dow JonesMay 9 16:02 ET

12 Health Care Stocks Moving In Wednesday's After-Market Session

GainersPulmonx (NASDAQ:LUNG) shares rose 29.5% to $10.0 during Wednesday's after-market session. The market value of their outstanding shares is at $388.1 million. The company's, Q1 earnings came out

BenzingaMay 1 16:31 ET

Market Outperform Rating Reiterated for Allakos Amid Promising AK006 Clinical Developments

TipRanksApr 24 00:25 ET

Hold Rating on Allakos Amidst Cautious Optimism for AK006 Program

TipRanksMar 19 01:38 ET

Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4

Yahoo FinanceMar 16 05:31 ET

Hold Rating on Allakos Amidst Clinical Pivots and Prospective AK006 Developments

TipRanksMar 15 08:05 ET

Analysts Are Bullish on These Healthcare Stocks: Allakos (ALLK), Century Therapeutics (IPSC)

TipRanksMar 15 07:10 ET